Pain and postoperative nausea and vomiting (PONV) are common and unpleasant symptoms after gynaecological laparoscopy [1] [2] [3] [4] . Both problems are associated with patient dissatisfaction, delayed hospital discharge and potentially more serious complications such as oesophageal rupture or pulmonary aspiration 5,6 . Both endotracheal tubes (ETT) and laryngeal mask airways (LMA) appear acceptable for suitable patients undergoing laparoscopic gynaecological surgery 7 . A number of small randomised trials 8-10 have directly compared the LMA ProSeal™ (Laryngeal Mask Company, Henley-on-Thames, UK) and ETT in gynaecological laparoscopy. These studies predominantly evaluated outcomes of safety and efficacy, including airway symptoms such as sore throat and hoarse voice.
Pain and postoperative nausea and vomiting (PONV) are common and unpleasant symptoms after gynaecological laparoscopy [1] [2] [3] [4] . Both problems are associated with patient dissatisfaction, delayed hospital discharge and potentially more serious complications such as oesophageal rupture or pulmonary aspiration 5, 6 . Both endotracheal tubes (ETT) and laryngeal mask airways (LMA) appear acceptable for suitable patients undergoing laparoscopic gynaecological surgery 7 . A number of small randomised trials [8] [9] [10] have directly compared the LMA ProSeal™ (Laryngeal Mask Company, Henley-on-Thames, UK) and ETT in gynaecological laparoscopy. These studies predominantly evaluated outcomes of safety and efficacy, including airway symptoms such as sore throat and hoarse voice.
Two recent studies 11, 12 by the same group of authors have shown the unexpected finding that surgical site pain, morphine requirements and PONV were all reduced with use of the LMA ProSeal, rather than endotracheal intubation, in female patients undergoing breast and gynaecological surgery. Although the protocols differed slightly between the studies, the findings were consistent. The authors postulated that use of the LMA ProSeal in the supraglottic region and the ETT in the subglottic region may impact neural pathways affecting pain and PONV differently. In this study we compared the incidence of pain and emetic symptoms using the LMA ProSeal and the ETT in suitable adult women undergoing laparoscopic gynaecological surgery at our institution.
A prospective randomised comparison of the LMA ProSeal™ versus endotracheal tube on the severity of postoperative pain following gynaecological laparoscopy J. D. GRIFFITHS*, M. NGUyEN †, H. LAU ‡, S. GRANT §, D. L. WILLIAMS** Department of Anaesthesia, Royal Women's Hospital, Melbourne, Victoria, Australia SUMMARy Pain and postoperative nausea and vomiting (PONV) are common problems after gynaecologic laparoscopy. Two recent studies have shown that morphine requirements and PONV are lower when a LMA ProSeal™ is used, rather than an endotracheal tube (ETT), for female patients undergoing breast and gynaecological surgery. We conducted a patient and observer-blinded randomised controlled trial, recruiting non-obese women without gastro-oesophageal reflux undergoing laparoscopic gynaecological surgery. Patients received a standardised relaxant general anaesthetic and then were randomised to receive either an LMA ProSeal or an endotracheal tube. Patients were assessed at two and 24 hours post-anaesthesia. The primary outcome was postoperative pain score and secondary endpoints included morphine consumption, postoperative emesis and adverse upper airway symptoms.
We recruited 116 patients to the study, 57 patients in the ETT group and 59 patients in the LMA ProSeal group. The patients were similar in demographic and surgical characteristics. At two hours, the ETT group was similar to the LMA ProSeal group in regards to pain scores (verbal rating scale 3.0 vs 3.5, P=0.86), morphine consumption (7.2 vs 7.4 mg, P=0.56) and PONV (47.4 vs 47.5%, P=0.99). After 24 hours, pain scores and PONV rates were also similar. No significant difference in rates of sore throat or dysphagia was observed between the ETT and LMA ProSeal groups. No significant complications were attributable to either airway device.
The LMA ProSeal did not decrease pain or PONV in patients undergoing gynaecological laparoscopy when compared to endotracheal intubation.
METHODS
We obtained approval for this trial from the Royal Women's Hospital Research and Ethics Committees and registered the trial with the Australia and New Zealand Clinical Trials Registry (Registration number: ACTRN12611000930987). We conducted a prospective, single-blind randomised controlled trial comparing the LMA ProSeal with an ETT for airway maintenance during general anaesthesia in healthy women undergoing gynaecological laparoscopy. Women were invited to participate during the preanaesthetic consultation on the day of surgery. Written information was provided and written informed consent was obtained prior to enrolment. Recruitment took place between March 2010 and June 2011.
We invited English speaking adult female patients of American Society of Anesthesiologists (ASA) physical status I-II to take part in the study, provided the anticipated surgical duration was between 30 and 120 minutes. Patients were excluded if they had a body mass index greater than 35 kg/m 2 , had chronic pain or were using opioids, had a history of severe PONV, had a sensitivity or contraindication to any study drug or a contraindication to a supraglottic airway device, such as gastro-oesophageal reflux, or a known or suspected difficult airway.
Randomisation was achieved using a computergenerated random sequence and concealed in sequentially numbered opaque envelopes. The envelopes were opened by the treating anaesthetist immediately prior to the induction of anaesthesia. The treating anaesthetist was aware of the group allocation but the patient and the outcome assessor/ data collector were blinded.
A standardised general anaesthetic technique was employed. Patients were pre-oxygenated prior to induction of general anaesthesia with propofol 1-2 mg/kg, fentanyl 1-3 µg/kg and atracurium 0.5 mg/ kg. Following induction, the allocated airway device was inserted. The LMA ProSeal was inserted using the bougie-guided technique described by Hohlrieder and colleagues 12 . The sizing of the LMA ProSeal was based on the manufacturer's weight-based guidelines (size 3: 30-50 kg; size 4: 50-70 kg; size 5: 70-100 kg). The LMA ProSeal insertion involved: obtaining the best possible view of the hypopharynx (pharyngoscopy) using a Macintosh laryngoscope blade; inserting a gum elastic bougie with its straight end first into the proximal 5 cm of the oesophagus; railroading the LMA ProSeal along its drain tube (gastric channel) into the pharynx; and cuff inflation with the appropriate volume of air to achieve an intra-cuff pressure of 60 cmH 2 O. The ETT (size internal diameter 7 mm, Mallinckrodt Medical) was inserted after obtaining the best possible view of the laryngeal inlet (vocal cords) using a Macintosh laryngoscope blade, and the cuff inflated to 20 cmH 2 O to ablate an audible leak.
All patients received intravenous paracetamol 1 g, parecoxib 40 mg and morphine titrated at the discretion of the treating anaesthetist to a maximum of 0.2 mg/kg. Anti-emetic prophylaxis consisted of a single dose of dexamethasone 4 mg. Maintenance of anaesthesia was achieved using sevoflurane in an oxygen/air mixture at an inspired oxygen concentration of 70-80%. No nitrous oxide was administered. During maintenance the patients' lungs were pressure control ventilated at an initial pressure of 15 cmH 2 O and a rate of 12 breaths per minute. During pneumoperitoneum peak airway pressures were increased as required to maintain an end-tidal carbon dioxide level of 40 mmHg. Muscle relaxation was reversed at the conclusion of surgery with neostigmine 2.5 mg and glycopyrrolate 400 µg. On emergence from anaesthesia, the airway device was removed and inspected for secretions and blood.
Intermittent nurse-administered intravenous morphine titration was used in the post-anaesthetic care unit until the verbal pain score was <4 (0-10 verbal numerical rating scale). Rescue anti-emetics consisted of granisetron 1 mg and droperidol 0.625 mg as required. If further opioid analgesia was required following discharge from the post-anaesthetic care unit, oxycodone 10 mg was prescribed.
The primary study endpoint was the postoperative pain score in the first two postoperative hours. Secondary outcomes included morphine consumption, postoperative emesis symptoms and adverse upper airway symptoms. At 24 hours postoperatively, patients were either visited on the ward or telephoned if they had been discharged from hospital. Pain scores, analgesic requirements, nausea and vomiting symptoms and adverse airway symptoms were sought.
Sample size calculation was based on a clinically significant difference of 25% between the groups for perioperative pain score, with a two-sided type I error of 0.05 and power of 0.8. A baseline mean pain score of 3.5 was obtained from a review of the medical records of 20 consecutive gynaecological laparoscopy patients at the Royal Women's Hospital in late 2009. An estimated standard deviation of 1.2 was determined from a similar published study 12 . This generated a required sample size of 60 patients in each arm of the trial.
Continuous data were assessed for normality and hypothesis testing was carried out using a Student's t-test or the Kruskall-Wallis test, as appropriate. Categorical data were tested using either the chisquare or Fisher's exact test, as appropriate. Statistical significance was defined by a P value <0.05.
RESULTS
We recruited 116 patients in the study (57 patients in the ETT group and 59 patients in the LMA ProSeal group). There were several minor protocol violations: three patients (one in the ETT group, two in the LMA ProSeal group) received alfentanil at induction of anaesthesia rather than fentanyl. All patients provided complete data intraoperatively and two hours postoperatively. Fourteen patients were unable to be contacted for the 24-hour follow-up, thus a total of 102 patients provided data at the 24hour timepoint (52 in the ETT group and 50 in the LMA ProSeal group) ( Figure 1) . The patients were comparable in demographic and surgical details ( Table 1) . There was no difference in the dose of intraoperative morphine given.
The LMA ProSeal was inserted successfully on the first attempt in 93% of cases (compared with 94% in the ETT group, P=0.63, Table 2 ). No device needed to be removed or repositioned once surgery had commenced. Blood was present on the device at removal in 16 % of ETT group and 12% of the LMA ProSeal group (P=0.56).
Two hours postoperatively, the ETT group had similar mean (standard deviation) morphine consumption to the LMA ProSeal group [7.2 (5.1) mg vs 7.4 (6.6) mg, P=0.56] and there was no significant difference in pain score [3.0 (2.0) mm vs 3.5 (2.2) mm, P=0.86]. The frequency of PONV, sore throat, hoarse voice and dysphagia did not differ between the groups, nor did the amount of time in spent in the post-anaesthetic care unit. Outcome data at 24 hours are presented in Table 3 . Pain scores and frequency of oral opioids consumed, PONV and sore throat did not differ between groups and no significant complications were attributable to either airway device.
DISCUSSION
Our study was designed to test the hypothesis that the LMA ProSeal is associated with lower rates of postoperative pain and emetic symptoms compared with the ETT. However, in our study, we found no apparent differences between either pain scores at two or 24 hours postoperatively or morphine consumption postoperatively. There were also no apparent differences in the incidence of PONV or adverse airway symptoms. A number of differences between our protocol and that of the Hohlrieder et al studies may explain our negative findings. First, Hohlrieder et al used only fentanyl and diclofenac for intraoperative analgesia, with morphine provided by patientcontrolled boluses in recovery. In contrast, we used paracetamol, parecoxib and anaesthetist-titrated morphine intraoperatively, with further morphine provided by nurse-initiated boluses postoperatively. This multimodal intraoperative analgesia may have reduced the apparent difference in pain scores that Holrieder et al observed. Hohlrieder provided no anti-emetic prophylaxis in one study 12 and a combination of dexamethasone and tropisetron in the other study 11 . We used single agent anti-emetic prophylaxis (dexamethasone) and this may have reduced our capacity to detect a difference between groups. However, the incidence of PONV in our study was very high despite this, and nearly 50% of our patients required treatment for PONV. This finding reinforces the observation that women undergoing gynaecological laparoscopy are at very high risk of PONV and should be considered for routine multipleagent prophylaxis 4, 5 .
In our study we decided not to use a gastric tube routinely in all patients, which may have increased the likelihood of PONV. Gastric distension is one of a number of potential risks of using the LMA Pro-Seal (compared with the ETT) for laparoscopic surgery. It is possible that this risk may warrant routine gastric tube placement. Our sample size calculation was based on a review of previous patients undergoing laparoscopy at our institution. However, our study found a greater variance in pain scores and morphine requirements than the pilot sample and therefore may have been underpowered to detect any difference. A future larger study may be able to quantify in more detail any influence of airway device on quality of recovery, including pain and nausea, following gynaecological laparoscopy.
CONCLUSION
This study found that, when compared with an endotracheal tube, the ProSeal LMA did not alter pain scores, analgesic requirements or emesis symptoms, in patients undergoing gynaecological laparoscopic surgery.
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